Enter your keyword

Efficiently Creating Value with Innovative Science

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ONCOTELIC THERAPEUTICS, INC. ANNOUNCES PRESENTATION AT AYURVEDIC PERSPECTIVES ON COVID-19.
AGOURA HILLS, Calif., March 31, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC) (f/k/a Mateon Therapeutics, Inc.) announced today that the Chopra Foundation and Jiva are collaborating to bring a webinar regarding new approaches for managing COVID-19
View HTML
Toggle Summary ONCOTELIC THERAPEUTICS, INC. {FORMERLY MATEON THERAPEUTICS, INC.) NAME AND SYMBOL CHANGE.
AGOURA HILLS, Calif., March 30, 2021 - Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC) (f/k/a Mateon Therapeutics, Inc.) announced today that the Financial Industry Regulatory Authority ("FINRA") has confirmed the change in the Company's name and approved the stock symbol
View HTML
Toggle Summary MATEON ANNOUNCES INITIATION OF PHASE 1B CLINICAL TRIAL ON OT-101/IL-2 COMBINATION THERAPY FOR SOLID TUMORS
AGOURA HILLS, California , March 15, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN) today announced the regulatory approval from the Ministry of Food and Drug Safety of Korea for the phase 1b clinical trial of a patented OT-101/IL-2 combination.
View HTML
Toggle Summary MATEON’S UPDATE ON C001 - GLOBAL STUDY FOR OT-101 AGAINST COVID-19
PART 1 AND 2 SENTINEL PATIENTS COMPLETED TREATMENT THE FIRST COHORT OF 18 PART 1 PATIENTS COMPLETED TREATMENT. AGOURA HILLS, Calif. , March 08, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (“Mateon”) (OTCQB:MATN) announced today that it has completed the enrollment of its sentinel Part 1 and
View HTML
Toggle Summary MATEON THERAPEUTICS AND WINDLAS BIOTECH PUBLISH PULMOHEAL™ CLINICAL DATA AGAINST COVID-19 IN PEER-REVIEWED JOURNALS
AGOURA HILLS, California , March 01, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious disease and respiratory health, and Windlas Biotech Pvt. Ltd. (Windlas), a leading Indian pharmaceutical contract
View HTML
Toggle Summary MATEON THERAPEUTICS AND WINDLAS BIOTECH LAUNCH INDIA’S FIRST COMBINED LUNG THERAPY AND AI TELEMEDICINE 360° SOLUTION TO TRANSFORM RESPIRATORY WELLNESS AT WWW.PULMOHEAL.COM
AGOURA HILLS, California , Feb. 22, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious disease and respiratory health and Windlas Biotech Pvt. Ltd. (Windlas), a leading Indian pharmaceutical contract drug
View HTML
Toggle Summary MATEON PARTNERED WITH CHOPRA FOUNDATION ON ARTIVEDA™
AGOURA HILLS, California , Feb. 16, 2021 (GLOBE NEWSWIRE) --   Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious disease and respiratory health, announced a global partnership with Chopra Foundation , a non-profit, to
View HTML
Toggle Summary MATEON ANNOUNCES COMPLETION OF ARTI-19 AND PUBLICATION OF POSITIVE INTERIM DATA
AGOURA HILLS, California , Feb. 02, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious diseases, announced that its ARTI-19 trial, evaluating ARTIVeda ™ / PulmoHeal ™ against COVID-19 in India , has
View HTML
Toggle Summary MATEON LAUNCHES ITS AI TELEMEDICINE PLATFORM FOR POST MARKETING SURVEY TO SUPPORT ITS DRUG PRODUCT FOR INDIA, PULMOHEAL™
AGOURA HILLS, California , Feb. 01, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious diseases, announce today that it has launched its artificial intelligence (AI) telemedicine platform for post
View HTML
Toggle Summary MATEON LAUNCHING MOBILE APP, ARTIHEALTH™, FOR REMOTE RESPIRATORY HEALTH ASSESSMENT
AGOURA HILLS, California , Jan. 25, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious diseases, announced that it will be launching its mobile app, ARTIHealth TM , for respiratory health assessment, in
View HTML